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Chronic Fatigue Syndrome: What Do We Know About Its 
Aetiology and Treatment? 
 
Yasir Abbasi, Waqqas Khokhar, Mohammed Mubashir Ali 
 
Abstract 
 
The historical development of the concept of chronic fatigue syndrome (CFS) as a 
disease entity as well as the proposed management strategies has been 
contentious.  This illness which is ever-growing has significant social, personal and 
economic costs for the society in general and the individuals suffering from it in 
particular. We acknowledge the heterogeneity of this syndrome and attempt to 
highlight the current evidence base around the aetiological hypothesis of this 
'mysterious' illness. Finally the treatments that can potentially affect the course, 
outcome and quality of life of the sufferers are discussed. The article calls for further 
research and development in order to reach a consensus on the diagnostic criteria 
and the determinants of biological and psychological parameters to serve as 
markers of treatment response.  
 
Key words: Chronic Fatigue Syndrome, Gulf War Syndrome, CBT, Psychiatric Co- 
Morbidity, Genetics, Myalgic Encephalomyelitis. 
 
Introduction 
 
Chronic fatigue syndrome (CFS), also known as Myalgic Encephalomyelitis (ME) or 
post viral fatigue syndrome, is not a new entity. In the 19th century a neurologist, 
George Beard (1869), used the term neurasthenia and nervous exhaustion for a 
condition resembling that of CFS. The term myalgic encephalomyelitis has also 
been used for symptoms resembling that of CFS in medical literature and was 
described in detail by Ramsay (1978).  
 
CFS has, to a certain extent, been a contentious diagnosis, especially with regards 
to its clinical definition and aetio-pathogenesi. Chronic Fatigue Syndrome fell into 
controversy again when the 1991 Gulf War Veterans complained of symptoms 
resembling those of CFS. Their illness was later dubbed Gulf War Syndrome 
(GWS).  However, large cohorts studied ten years after the first Gulf War did show 
that the veterans were at increased risk of Fibromyalgia, CFS and other medical 
illnesses (Eisen et al, 2005). 
 
The Centre for Disease Control (CDC) in 1988 introduced the term chronic fatigue 
syndrome (Holmes et al, 1988). Later, they used the term chronic fatigue and 
immune dysfunction syndrome (CFIDS) in an attempt to reduce the psychiatric 
stigma often associated with CFS (Jason et al, 2005). CFS is classified under 
Chapter 6 (G Code) of the International Classification of Diseases-10th edition, i.e. 
Diseases of the Nervous System (WHO, 1990).  
 
Most definitions warrant a number of features to be present before a diagnosis can 
be made. The most common being severe mental and physical depletion for more 
than 6 months which, according to Fukuda et al (1994), is unrelieved by rest, and is 
usually made worse by even trivial exertion. There is, however, no consistent 
method which would allow objective measures, such as blood tests or brain scans, 
to diagnose CFS with certainty. Unsurprisingly, therefore, the biggest hurdle 
encountered in the management of CFS is the diagnosis. There are numerous 
symptoms which patients can experience but the common ones include cognitive 
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difficulties (short term memory loss), sore throat, myalgia, lymphadenopathy, 
arthralgia and fatigue following exertion, lasting for days. The above should usually 
be present for longer than six months according to the CDC criteria as well (Holmes 
et al, 1988). 
 
A recent review by Cho et al (2006) concluded that more research is required to 
improve the current case definition, as investigations overlap and boundaries among 
various functional somatic syndromes are fluid. This should help us to understand 
whether the pathophysiological findings in CFS are a cause or consequence of 
illness, as well as clarifying the interplay between the central nervous system, 
immunological and genetic factors.   
 
Aetiology: 
 
A variety of factors have been hypothesized in the aetiology of CFS (Table 1) but to 
date, no definitive cause has been singled out. Hypotheses regarding the causes of 
CFS are discussed below: 
 
Table 1 
 
Possible Aetiologies for Chronic Fatigue Syndrome: 
 
Hormonal and Central Nervous System factors 
 
Viral or other infectious agents and immune dysfunction 
 
Genetic Factors 
 
Psychiatric co-morbidity 
 
Other Factors 
i) Sleep Disturbance 
ii) Exercise Intolerance 
iii) Neurally Mediated Hypotension  
iv) Hyperventilation 
 
 
1. Hormonal and Central Nervous System Factors: 
 
Cleare (2004) suggested that there is under-activity of the hypothalamopituitary-
adrenal (HPA) axis in most patients diagnosed with CFS. This leads to a lower 
cortisol level, suggesting an endocrinological basis to the illness.  Another study by 
Cleare et al (1999) on the diurnal patterns of salivary cortisol and cortisone output in 
chronic fatigue syndrome provides further evidence for reduced basal HPA axis 
function in at least some patients with CFS. 
 
2. Viral or Other Infectious Agents and Immune Dysfunction: 
According to De Becker et al (2002) three-quarters of patients with the disorder have 
reported an infection, such as a cold, flu-like illness, or infectious mononucleosis, as 
the trigger. White et al (2001) found a causal relation between infectious 
mononucleosis and chronic fatigue. Ablashi (1994) thought that Epstein-Barr virus, 
human herpes virus 6, group B Coxsackie virus, human T-cell lymphotrophic virus II, 
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hepatitis C, enteroviruses, and retroviruses were of significance in chronic fatigue 
syndrome, implying a damaged immune system resulting from infection. Other 
organisms have also been implicated and particularly high rates of chronic fatigue 
have been found following Q-fever and Lyme disease.  However, Swanink et al 
(1995) found no differences in viral loading of Epstein-Barr virus and immunological 
reactivity between individuals who developed CFS and those who did not.  Not all 
CFS sufferers show signs of previous infection and experts remain divided as to 
whether infection has any causative role in the disorder.  
Another study (Peakman et al, 1997) focused on cytokines and shifts in T-
lymphocyte subsets with variable results. A study of monozygotic twins discordant 
for CFS (Sabath et al, 2002) also failed to provide support for immunological 
abnormalities. 
3. Genetic Factors 
A twin study done by Buchwald et al (2001) has shown a familial predisposition 
where the concordance rates were higher between monozygotic than dizygotic 
twins.  They suggested that interaction between genetics and environment plays an 
important role in the aetiology of CFS.  Similarly, Sullivan et al (2005) in a study of 
twins in a Swedish national sample concluded that illness with marked symptoms of 
chronic fatigue appears to result from both environmental and genetic sources of 
variation, without pronounced differences in gender.  Smith et al (2005), found that 
CFS might be associated with HLA DQA1*01 locus.    
4. Psychiatric Co-Morbidity 
This has been controversial with certain researchers believing CFS to be primarily a 
functional illness (Stewart 1990) while others affirm that it has many organic 
components. Indeed, CFS sufferers have a higher incidence of psychiatric morbidity 
including severe depressive disorder (Manu et al 1989); generalised anxiety 
disorder (Kruesi et al, 1989), and somatoform disorder (Manu et al, 1993).  
According to Johnson et al (1996), if healthcare professionals attribute CFS to 
physical rather than psychiatric disorder, the rate of diagnosis falls dramatically.  
This is especially true of somatoform disorders.  More research is needed on the 
temporal relationship between chronic fatigue symptoms and psychiatric illness. 
   
5.  Other Factors: 
 
• Sleep Disturbance - According to Krupp et al (1993) sleep disruption does not 
appear to correlate with fatigue severity but at the same time they concluded that 
subjective sleep disturbance is common in CFS and some patients may have 
sleep disorders. 
 
• Exercise Intolerance - It is a possibility that patients with CFS might have some 
intrinsic inability to tolerate exercise. Lane et al (1998) suggested increase in 
lactic acid in response to exercise, while Wagenmakers et al (1988) felt that a 
reduction in number of muscle mitochondria is likely to be blamed for the 
reduced exercise intolerance. These findings are in the process of being 
validated by larger studies. 
 
• Neurally Mediated Hypotension – Wilke et al (1998) formulated after combining 
the results from various related studies that some patients diagnosed with CFS 
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have abnormal vasovagal or vasodepressor responses to upright posture. These 
findings, if validated, by larger controlled trials may help explaining some of the 
somatic symptoms of CFS.    
 
• Hyperventilation - Hyperventilation has also been theorised to play a causal or 
maintaining role in CFS. Van der Meer et al (1997) suggested that there was 
more physiological evidence for hyperventilation in patients with CFS than 
healthy individuals but that it should be regarded as an epiphenomenon. 
However, earlier suggestions in a study by Saisch et al (1994) only indicated a 
weak association between hyperventilation and CFS. 
Treatments 
There are a number of options and approaches which can be used for the treatment 
of CFS (Table 2).  However, the emphasis should be on a tailored approach to suit 
individual needs and requirements. Maquet et al (2006) suggested that a bio 
psychosocial approach and progressive muscular rehabilitation combined with 
behavioural and cognitive treatments should form an essential part of the holistic 
approach in managing the heterogeneous symptoms of the CFS complex. 
Table 2 
 
Different treatment options 
 
 
 
Biological 
 Antidepressants 
Corticosteroids 
Immunoglobulin 
Anti-viral & Anti-Microbial 
Others 
 
Psychological CBT 
 
Non-Pharmacological Graded Exercise Therapy (GET) 
Activity Management 
Sleep Management 
Relaxation Techniques 
1. Non- Pharmacological approach 
• Graded Exercise Therapy: Saggini et al (2006) proposed that rehabilitative 
exertion was a useful treatment for CFS patients. In another study Van der Meer 
et al (2005), also established that exercise improved fatigue symptoms in CFS 
patients but there was no change in overall level of activity. Rimes et al (2005) 
did a literature review to evaluate the treatment options available for CFS and 
found promising results with graded exercise combined with cognitive behaviour 
therapy. 
• Cognitive Behavioural Therapy: There is growing evidence to support the use 
of CBT either alone or in combination with other forms of treatment in CFS. In a 
randomised control trial Deale et al (1997) observed a 70% improvement in 
physical activities in patients with CFS who received 13-16 sessions of CBT as 
compared to controls who received relaxation therapy. Chisholm et al (2001) 
also concluded that counselling and CBT, both showed improvement in fatigue 
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and related symptoms. In a multicentre randomised controlled trial Prins et al 
(2001) observed that CBT was more effective than guided support groups. 
These improvements are noted to have been sustained over a period of 6-14 
months.  
2. Pharmacological Approach 
• Antidepressants: Psychiatrists are often called in to help managing the 
symptoms of CFS by the multi-disciplinary team especially where the affective 
symptoms are a cause of concern. White et al (1997) studied the effects of 
moclobemide on CFS and suggested that in the absence of a co-morbid 
depressive disorder, the use of this medication should be limited. Hartz et al 
(2003) in a randomised controlled trial studied the effects of Citalopram in 
patients with idiopathic chronic fatigue. They measured the improvement in CFS 
sufferers with the Rand Vitality index and concluded that Citalopram may 
improve fatigue and symptoms associated with fatigue for some patients. 
However, there is no conclusive evidence to support the use of antidepressants 
in CFS. 
 
• Corticosteroids: In a randomised controlled clinical trial Cleare et al (1999) 
used low dose Hydrocortisone to reduce fatigue in the short term. However, 
Blockmans et al (2003) in a randomised, placebo-controlled, double blind 
crossover study concluded that low-dose combination therapy of hydrocortisone 
and fludrocortisone was not effective in patients with chronic fatigue syndrome. 
Long term, follow up studies are required to see if any benefits achieved are 
long lived and clinically useful. 
 
• Immunoglobulin: It is only natural to explore the role of Immunoglobulin since 
immune dysfunction has been hypothesised as a potential factor in the aetiology 
of CFS (Ablashi, 1994). In a randomized, double-blind, placebo-controlled trial to 
determine the effectiveness of high-dose intravenously administered 
immunoglobulin G, Lloyd et al (1990) found that immunomodulator treatment 
with immunoglobulin is effective in a significant number of patients with CFS.  
 
• Antiviral & Antimicrobial: There is weak evidence that such treatments would 
help, as no infectious cause has been established yet. Acyclovir has been found 
to be ineffective (Straus et al 1988; Iwakami et al 2005).  
 
• Other Treatments: The use of Essential Fatty Acids (Warren et al 1999), 
reduced form of oral nicotinamide adenine dinucleotide (Forsyth et al 1999) and 
Selegiline (Natelson et al 1998) has been of little value without any promising 
results. An experimental medication Ampligen, a synthetic nucleic acid 
Poly(I).Poly(C12U) is being studied for potential use in patients with CFS. 
3. Alternative Approaches 
When symptoms are unrelieved by conventional medicine, it’s not uncommon for 
sufferers of CSF to turn to alternative and or complementary methods. These 
treatments include megavitamins; herbal therapies; special diets and adenosine 
monophosphate, iron, magnesium sulphate, melatonin and zinc supplements (Jens, 
2005). However, randomised control trials to determine the effectiveness of these 
treatments are almost nonexistent. 
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Conclusion 
Chronic Fatigue Syndrome is heterogeneous in presentation and this may point 
towards a similar aetiology. It would therefore, require a multi-disciplinary approach 
to diagnosing and treating the intriguing symptoms of this ‘mysterious’ illness. 
Especially, when there is still some doubt and stigma attached to the very process of 
diagnoses and the sufferers alike (Jason, 2004). 
The support of the scientific community to undertake further research into exploring 
this multi-faceted illness is imperative to achieve the above mentioned aims. The 
first hurdle for patients is being diagnosed. Therefore, serious attempts should be 
made to develop universally acceptable and applicable diagnostic criteria. The 
importance of identifying a range of biological and psychological parameters as 
markers for treatment cannot be undermined either. The increased variety of 
outcome measures used in the studies quoted in this article makes standardisation 
of outcomes a priority for future research.  
The second hurdle is to get the right help from the right services and appropriate 
management for it. At the moment most patients in England and Wales are 
managed either by their GP’s or referred to psychiatrists and/or neurologists for 
advice. Instead, there is a need to develop specialist services for these patients, 
which can provide holistic input in managing CFS with emphasis on graded activity 
and exercise and collaboratively work with the patients to develop individually 
tailored recovery plans. Hence, we need to remodel our current services and build 
specialist diagnostic and rehabilitation centres for CFS sufferers all over the country, 
like the one established by Barking, Havering and Redbridge University Hospitals 
NHS Trust. (http://www.bhrhospitals.nhs.uk/cfs/cf1.php).  
Chronic Fatigue Syndrome has survived the test of time and is likely here to stay as 
a complex illness. It is therefore essential that the ‘true’ prevalence of this illness in 
the community is recognised and determined sincerely. This can be achieved by 
setting up multi-site epidemiological studies across the world. 
 It is also imperative that good care of our patients, integrate medical and 
psychological concepts, together with symptomatic management. This may help to 
prevent significant secondary impairment in the majority of patients and could help 
to improve the quality of life of the sufferers.  
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